A Clinical Trial of Oral Suberoylanilide Hydroxamic Acid (SAHA) in Patients With Advanced Multiple Myeloma (0683-004)
Status:
Terminated
Trial end date:
2006-02-14
Target enrollment:
Participant gender:
Summary
The purposes of this study are:
- To determine the maximum tolerated dose (MTD) of SAHA administered every 12 hours for 14
consecutive days followed by 7 days of rest during the first two cycles (i.e., first 6
weeks) in patients with advanced multiple myeloma;
- To assess the safety and overall response rate to SAHA in patients with advanced
multiple myeloma.